Fangchinoline inhibits human immunodeficiency virus type 1 replication by interfering with gp160 proteolytic processing

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Wan, Zhitao ^a   Lu, Yimei ^a   Liao, Qingjiao ^a   Wu, Yang ^a   Chen, Xulin ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; FANGQUINOLINE; FLAVOPIRIDOL; GLYCOPROTEIN GP 160; INDINAVIR; INTEGRASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; HERB; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PLANT ROOT; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STEPHANIAE TETRANDRAE; VESICULAR STOMATITIS VIRUS; VIRION; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN;

BENZYLISOQUINOLINES; BLOTTING, WESTERN; CELL LINE; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; PROTEOLYSIS; VIRUS REPLICATION;

EID: 84862224260     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039225     Document Type: Article

References (35)

1. Carr A, Cooper DA, (2000) Adverse effects of antiretroviral therapy. The Lancet 356: 1423 1430.
2. Montessori V, Press N, Harris M, Akagi L, Montaner JSG, (2004) Adverse effects of antiretroviral therapy for HIV infection. Canadian Medical Association Journal 170: 229 238.
3. Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J, (2008) The spread, treatment, and prevention of HIV-1: evolution of a global pandemicJournal of Clinical Investigation. The Journal of Clinical Investigation 118: 1244 1254.
4. Clavel F, Hance AJ, (2004) HIV drug resistance. New England Journal of Medicine 350: 1023 1035.
5. Checkley MA, Luttge BG, Freed EO, (2011) HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. Journal of Molecular Biology 410: 582 608.
6. Moulard M, Decroly E, (2000) Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes 1469: 121 132.
7. McCune JM, Rabin LB, Feinberg MB, Lieberman M, Kosek JC, (1988) Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53: 55 67.
8. Jiang Y, Liu X, De Clercq E, (2011) New therapeutic approaches targeted at the late stages of the HIV-1 replication cycle. Current Medicinal Chemistry 18: 16 28.
9. Sabatier JM, Mabrouk K, Moulard M, Rochat H, Van Rietschoten J, (1996) Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus Type 1 envelope. Virology 223: 406 408.
10. Barbouche R, Sabatier JM, Fenouillet E, (1998) An anti-HIV peptide construct derived from the cleavage region of the Env precursor acts on Env fusogenicity through the presence of a functional cleavage sequence. Virology 247: 137 143.
11. Barbouche R, Decroly E, Kieny MP, Fenouillet E, (2000) An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane susion at a post-CD4 binding step. Virology 273: 169 177.
12. Cameron A, Appel J, Houghten RA, Lindberg I, (2000) Polyarginines are potent furin inhibitors. Journal of Biological Chemistry 275: 36741 36749.
13. Kibler KV, Miyazato A, Yedavalli VSRK, Dayton AI, Jacobs BL, (2004) Polyarginine Inhibits gp160 processing by furin and suppresses productive human immunodeficiency virus type 1 infection. Journal of Biological Chemistry 279: 49055 49063.
14. Adessi C, Soto C, (2002) Converting a peptide into a drug: Strategies to improve stability and bioavailability. Current Medicinal Chemistry 9: 963 978.
15. Thomas G, (2002) Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nature Reviews: Molecular Cell Biology 3: 753 766.
16. José ES, Muñoz-Fernández MA, Alarcón B, (1997) Megalomicin inhibits HIV-1 replication and interferes with gp160 processing. Virology 239: 303 314.
17. Dewar RL, Vasudevachari MB, Natarajan V, Salzman NP, (1989) Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport. Journal of Virology 63: 2452 2456.
18. Gruters RA, Neefjes JJ, Tersmette M, de Goede REY, Tulp A, (1987) Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature 330: 74 77.
19. Blair WS, Cao J, Jackson L, Jimenez J, Peng Q, (2007) Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing. Antimicrobial Agents and Chemotherapy 51: 3554 3561.
20. Vlietinck AJ, De Bruyne T, Apers S, Pieters LA, (1998) Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) Infection. Planta Medica 64: 97,109.
21. Saklani A, Kutty SK, (2008) Plant-derived compounds in clinical trials. Drug Discovery Today 13: 161 171.
22. Miyake A, Ishida T, Yamagishi M, Hara T, Umezawa K, (2010) Inhibition of active HIV-1 replication by NF-κB inhibitor DHMEQ. Microbes and Infection 12: 400 408.
23. Wan H, Seth A, Rainen L, Fernandes H, (2010) Coamplification of HIV-1 proviral DNA and viral RNA in assays used for quantification of HIV-1 RNA. Journal of Clinical Microbiology 48: 2186 2190.
24. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC, (2009) Evidence that ecotropic murine leukemia virus contamination in TZM-bl Cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. Journal of Virology 83: 8289 8292.
25. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, (2003) PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proceedings of the National Academy of Sciences 100: 13555 13560.
26. Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, (2010) HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathogens 6: e1001220.
27. Blair WS, Cao J, Fok-Seang J, Griffin P, Isaacson J, (2009) New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. Antimicrobial Agents and Chemotherapy 53: 5080 5087.
28. Kim HS, Zhang YH, Oh KW, Ahn HY, (1997) Vasodilating and hypotensive effects of fangchinoline and tetrandrine on the rat aorta and the stroke-prone spontaneously hypertensive rat. Journal of Ethnopharmacology 58: 117 123.
29. Moulard M, Montagnier L, Bahraoui E, (1994) Effects of calcium ions on proteolytic processing of HIV-1 gp160 precursor and on cell fusion. FEBS Letters 338: 281 284.
30. Alexander DJ, (2007) An overview of the epidemiology of avian influenza. Vaccine 25: 5637 5644.
31. Pal R, Gallo RC, Sarngadharan MG, (1988) Processing of the structural proteins of human immunodeficiency virus type 1 in the presence of monensin and cerulenin. Proceedings of the National Academy of Sciences 85: 9283 9286.
32. Pal R, Hoke GM, Sarngadharan MG, (1989) Role of oligosaccharides in the processing and maturation of envelope glycoproteins of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences 86: 3384 3388.
33. Walker BD, Kowalski M, Goh WC, Kozarsky K, Krieger M, (1987) Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proceedings of the National Academy of Sciences 84: 8120 8124.
34. Aiken C, Chen CH, (2005) Betulinic acid derivatives as HIV-1 antivirals. Trends in Molecular Medicine 11: 31 36.
35. Fujioka T, Kashiwada Y, Kilkuskie RE, Cosentino LM, Ballas LM, (1994) Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. Journal of Natural Products 57: 243 247.